keyword
MENU ▼
Read by QxMD icon Read
search

CD30

keyword
https://www.readbyqxmd.com/read/29905579/a-case-of-alk-anaplastic-large-cell-lymphoma-with-aberrant-myeloperoxidase-expression-and-initial-cutaneous-presentation
#1
Alejandro A Gru, Patrick J Voorhess
Anaplastic large-cell lymphoma (ALCL) was first described in 1985 by Stein et al and is a clinically, morphologically, and immunophenotypically heterogeneous neoplasm characterized by ALK expression, rearrangement of the ALK gene, and most characteristically its occurrence in children. Clinically, cutaneous ALK+ ALCL can be divided into primary (cutaneous forms) and the much more common, secondary dissemination by a systemic lymphoma. Systemic ALK+ ALCL represents 10%-15% of childhood non-Hodgkin lymphoma and generally presents with advanced systemic disease...
November 27, 2017: American Journal of Dermatopathology
https://www.readbyqxmd.com/read/29898383/foxp3-positive-t-cell-lymphomas-in-non-htlv1-carriers-include-alk-negative-anaplastic-large-cell-lymphoma-expanding-the-spectrum-of-t-cell-lymphomas-with-regulatory-phenotype
#2
Cristiane R Ferreira, Shuchun Zhao, Malaya K Sahoo, Benjamin Pinsky, Jenna Weber, Luis A P C Lage, Juliana Pereira, Maria C N Zerbini, Yasodha Natkunam
Forkhead box P3 (FOXP3) is a specific marker for regulatory T-cells (Tregs). We report 6 cases of T-cell lymphomas with Treg phenotype based on diffuse positivity for FOXP3 in tumor cells. The patients showed a median age of 56years with a male predominance. Sites of disease included lymph nodes (4), skin (2), subcutaneous tissue (1) and bone marrow (1). All cases showed monomorphic large cells, some with Hodgkin-like or anaplastic cells. All cases expressed pan T cell markers and lacked cytotoxic markers; one case showed diffuse PD1 staining...
June 10, 2018: Human Pathology
https://www.readbyqxmd.com/read/29893430/tcr-%C3%AE-expression-and-%C3%AE-%C3%AE-t-cell-infiltrates-in-primary-cutaneous-gamma-delta-t-cell-lymphoma-and-other-cutaneous-t-cell-lymphoproliferative-disorders
#3
Melissa Pulitzer, Shamir Geller, Erica Kumar, Denise Frosina, Allison Moskowitz, Steven Horwitz, Patricia Myskowski, Meenal Kheterpal, Alexander Chan, Ahmet Dogan, Achim Jungbluth
AIMS: The diagnosis of cutaneous gamma delta T-cell lymphoma (GDTCL) requires the identification of γδ chains of the T-cell receptor (TCR). Using a new mAb to TCRδ, we evaluated TCRδ expression in formalin fixed paraffin embedded (FFPE) skin tissue from TCRγ-positive cutaneous T-cell lymphoma (CTCL) and assessed TCRδ expression within a spectrum of other cutaneous lymphoproliferative disorders (CLPD). METHODS AND RESULTS: 12 cases (10 patients) with TCRγ-positive CTCL and 132 additional CLPD cases (127 patients) were examined including mycosis fungoides (MF, n=60), cutaneous GDTCL (n=15), subcutaneous panniculitis-like T-cell lymphomas (SPTCL, n=11), and CD30+ lymphoproliferative disorders (CD30+LPDs, n=24)...
June 12, 2018: Histopathology
https://www.readbyqxmd.com/read/29889102/human-cd30-b-cells-represent-a-unique-subset-related-to-hodgkin-lymphoma-cells
#4
Marc A Weniger, Enrico Tiacci, Stefanie Schneider, Judith Arnolds, Sabrina Rüschenbaum, Janine Duppach, Marc Seifert, Claudia Döring, Martin-Leo Hansmann, Ralf Küppers
Very few B cells in germinal centers (GCs) and extrafollicular (EF) regions of lymph nodes express CD30. Their specific features and relationship to CD30-expressing Hodgkin and Reed/Sternberg (HRS) cells of Hodgkin lymphoma are unclear but highly relevant, because numerous patients with lymphoma are currently treated with an anti-CD30 immunotoxin. We performed a comprehensive analysis of human CD30+ B cells. Phenotypic and IgV gene analyses indicated that CD30+ GC B lymphocytes represent typical GC B cells, and that CD30+ EF B cells are mostly post-GC B cells...
June 11, 2018: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/29886583/-clinicopathologic-features-of-primary-mucosal-cd30-positive-t-cell-lymphoproliferative-disorders-in-head-and-neck-region
#5
F Liu, M Li, L Y Zhang, L Guo, W W Hu, H L Rao
Objective: To study clinicopathologic features, prognosis and differential diagnoses of primary mucosal CD30-positive T-cell lymphoproliferative disorders of the head and neck(mCD30(+) TLPD-head and neck). Methods: Three cases of mCD30(+) TLPD-head and neck were collected from January 2014 to April 2017 at Sun Yat-Sen University Foshan Hospital. A literature review of mCD30(+) TLPD of head and neck was provided. Results: All three cases presented with either bulging/exophytic nodule or mucosal ulcer/erosion...
June 8, 2018: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/29882363/positive-impact-of-brentuximab-vedotin-on-overall-survival-of-patients-with-classical-hodgkin-lymphoma-who-relapse-or-progress-after-autologous-stem-cell-transplantation-a-nationwide-analysis
#6
Panagiotis Tsirigotis, Theodoros Vassilakopoulos, Ioannis Batsis, Zoi Bousiou, Konstantinos Gkirkas, Ioanna Sakellari, Panayotis Kaloyannidis, Paraskevi Roussou, Gerassimos A Pangalis, Maria Moschogiannis, George Vassilopoulos, Panagiotis Repousis, Aekaterini Megalakaki, Eurydiki Michalis, Christina Kalpadakis, Helen A Papadaki, Ioannis Kotsianidis, Eleftheria Hatzimichael, Alexandros Spyridonidis, Konstantinos Anargyrou, Elias Poulakidas, Panagiota Giannoullia, Ioannis Apostolidis, Maria Stamouli, Konstantinos Konstantopoulos, Vassiliki Pappa, Panayiotis Panayiotidis, Nikolaos Harhalakis, Achilles Anagnostopoulos, Maria Angelopoulou
The outcome of patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL) after autologous stem cell transplantation (auto-SCT) is poor. Recently, the anti-CD30 monoclonal antibody-drug conjugate, brentuximab vedotin (BV), has shown remarkable activity in the setting of R/R cHL. In the pivotal phase II study, BV produced an overall response rate of 75% and a median progression-free survival of 6.7 months. Although these results have been reproduced by large registry studies, the impact of BV on the overall survival (OS) of patients with R/R cHL has not been addressed so far...
June 8, 2018: Hematological Oncology
https://www.readbyqxmd.com/read/29881891/-primary-cutaneous-lymphoma-a-case-series-of-163-patients
#7
D Nashan, C M Friedrich, E Geissler, A Schmitt-Graeff, F Klein, F Meiss
BACKGROUND: In addition to a broad and clinically diverse spectrum of known primary cutaneous lymphomas, for which an incidence of 1-3:100,000 is postulated, each year further entities are specified and defined. The goal is the presentation of a case series from daily clinical routine. METHODS: Over a period of 6 years and 2 months, patients consulting the Department of Dermatology, Medical Center University of Freiburg, were registered. Subsequently, collectives of mycosis fungoides (MF), Sezary syndrome (SS), CD30+ lymphoproliferative diseases, single cases with rare primary cutaneous lymphomas, and subcollectives of B‑cell lymphomas were examined...
June 7, 2018: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/29851705/pityriasis-lichenoides-atypical-pityriasis-lichenoides-and-related-conditions-a-study-of-66-cases
#8
Tiziana Borra, Ana Custrin, Andrea Saggini, Regina Fink-Puches, Carlo Cota, William Vermi, Fabio Facchetti, Lorenzo Cerroni
Pityriasis lichenoides (PLs) is an uncommon skin disease of unknown etiology. In recent years, an atypical form of PL has been described, showing overlapping features with mycosis fungoides (MF) and lymphomatoid papulosis. We studied 66 patients with an initial histopathologic diagnosis of PL (M:F=34:32; median age, 25 y; range, 7 to 85 y). According to clinical and phenotypic features, cases were classified into 4 categories: (1) Conventional PL (characteristic clinical features of PL without phenotypic aberrations) (n=20; M:F=8:12; median age, 37 y; range, 9 to 74 y); (2) Atypical form of PL (characteristic clinical features of PL with phenotypic aberrations) (n=25; M:F=16:9; median age, 21 y; range, 7 to 72 y)...
May 30, 2018: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/29848986/the-transition-between-telomerase-and-alt-mechanisms-in-hodgkin-lymphoma-and-its-predictive-value-in-clinical-outcomes
#9
Radhia M'kacher, Corina Cuceu, Mustafa Al Jawhari, Luc Morat, Monika Frenzel, Grace Shim, Aude Lenain, William M Hempel, Steffen Junker, Theodore Girinsky, Bruno Colicchio, Alain Dieterlen, Leonhard Heidingsfelder, Claire Borie, Noufissa Oudrhiri, Annelise Bennaceur-Griscelli, Olivier Moralès, Sarah Renaud, Zoé Van de Wyngaert, Eric Jeandidier, Nadira Delhem, Patrice Carde
Background : We analyzed telomere maintenance mechanisms (TMMs) in lymph node samples from HL patients treated with standard therapy. The TMMs correlated with clinical outcomes of patients. Materials and Methods : Lymph node biopsies obtained from 38 HL patients and 24 patients with lymphadenitis were included in this study. Seven HL cell lines were used as in vitro models. Telomerase activity (TA) was assessed by TRAP assay and verified through hTERT immunofluorescence expression; alternative telomere lengthening (ALT) was also assessed, along with EBV status...
May 30, 2018: Cancers
https://www.readbyqxmd.com/read/29846244/markers-of-the-hiv-1-reservoir-facts-and-controversies
#10
Timothée Bruel, Olivier Schwartz
PURPOSE OF REVIEW: The HIV-1 reservoir is composed of infected cells poised to replicate and spread the virus upon treatment interruption. It constitutes the main obstacle toward an HIV-1 cure. Whether marker(s) may allow the detection of cells that form the reservoir is an outstanding question. Here, we present and discuss recent advances and controversies in the identification and characterization of markers of the HIV-1 reservoir. RECENT FINDINGS: Latently infected T cells that persist under successful therapy do not express viral antigens, making their identification challenging...
May 24, 2018: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/29843820/successful-treatment-of-primary-bone-marrow-hodgkin-lymphoma-with-brentuximab-vedotin-a-case-report-and-review-of-the-literature
#11
Keiki Nagaharu, Masahiro Masuya, Yuki Kageyama, Takanori Yamaguchi, Ryugo Ito, Keiki Kawakami, Masafumi Ito, Naoyuki Katayama
BACKGROUND: Hodgkin lymphoma usually presents with sequential enlargement of peripheral lymph nodes, and bone marrow invasion rarely occurs (approximately 3-5%). However, several cases have been reported as "primary" bone marrow Hodgkin lymphoma, especially among patients with human immunodeficiency virus and the elderly. This type of Hodgkin lymphoma is characterized by no peripheral lymphadenopathies and has been reported to have poorer prognosis. CASE PRESENTATION: A 38-year-old Japanese man was admitted to our hospital because of fever of unknown origin and pancytopenia without lymphadenopathies...
May 30, 2018: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29806104/dermal-xanthomatous-infiltrates-after-brentuximab-vedotin-therapy-in-mycosis-fungoides-with-large-cell-transformation-a-novel-histologic-finding
#12
Natalia Buchely, Rami Al-Rohil, Phyu P Aung, George Jour, Carlos Torres-Cabala, Victor G Prieto, Doina Ivan
Mycosis fungoides (MF) is the most common variant of cutaneous T-cell lymphomas (CTCL). Large cell transformation of MF has been associated with disease progression and overall poor outcome. The expression of CD30, which defines anaplastic large cell lymphoma (ALCL) and lymphomatoid papulosis (LyP), might also occur in a subset of patients with MF, with or without large cell transformation. Brentuximab vedotin is an anti-CD30 monoclonal antibody which has been proven to be a safe and effective therapeutic agent in the treatment of CD30-positive lymphomas, such as Hodgkin lymphoma and ALCL...
May 27, 2018: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/29805352/hemophagocytic-lymphohistiocytosis-secondary-to-unknown-underlying-hodgkin-lymphoma-presenting-with-a-cholestatic-pattern-of-liver-injury
#13
REVIEW
A L Booth, P Osehobo, D Rodgers-Soriano, A Lalarukh, M A Eltorky, H L Stevenson
Hemophagocytic lymphohistiocytosis (HLH) is an uncommon disease that often presents with nonspecific findings. A high index of suspicion is necessary to make a prompt diagnosis and prevent fatal disease. A 45-year-old man presented with fever, hypotension, abdominal pain, nausea, and vomiting. Imaging showed hepatosplenomegaly and laboratory tests revealed pancytopenia, increased ferritin, and a cholestatic pattern of injury with elevated alkaline phosphatase and total bilirubin. Due to a history of Crohn disease, systemic lupus erythematous, and rheumatoid arthritis, the patient was on immunosuppressants, including infliximab...
January 2018: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/29803640/loss-of-5-hydroxymethylcytosine-is-an-epigenetic-biomarker-in-cutaneous-t-cell-lymphoma
#14
Lei Qiu, Fengjie Liu, Shengguo Yi, Xueying Li, Xiaoqing Liu, Cheng Xiao, Christine Guo Lian, Ping Tu, Yang Wang
DNA hydroxymethylation at the 5 position of cytosine (5-hmC) is a product of the ten-eleven translocation (TET) family of DNA hydroxylases. Accumulating evidence shows that loss of 5-hmC is critical for various biological and pathological processes. However, its level in cutaneous T cell lymphoma remains largely unknown. Here we report that the loss of 5-hmC is an epigenetic hallmark of cutaneous T cell lymphoma (CTCL), with diagnostic and prognostic implications. Immunohistochemistry staining on 90 mycosis fungoides (MF) cases demonstrated a significant decrease of 5-hmC staining in CD4+ T cells in patch and tumor stages, especially in MF-LCT, compared to benign inflammatory dermatoses...
May 24, 2018: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/29794740/prevalence-of-cd30-immunostaining-in-neoplastic-mast-cells-a-retrospective-immunohistochemical-study
#15
Geisilene Russano de Paiva Silva, Emilie Tournier, Luis Otávio Sarian, Cristina Bulai-Livideanu, Georges Delsol, Laurence Lamant, José Vassallo, Pierre Brousset, Camille Laurent
Mastocytosis is a rare disease characterized by clonal neoplastic proliferation of mast cells (MCs). It ranges from skin lesions as cutaneous mastocytosis (CM) which may spontaneously regress to highly aggressive neoplasms with multiorgan involvement corresponding to some aggressive systemic mastocytosis (ASM), mast cell leukemia (MCL), and/or mast cell sarcoma (MCS).There is increasing evidence of CD30 expression in neoplastic MCs of the bone marrow. This expression has been described almost exclusively in aggressive forms of systemic mastocytosis (SM)...
May 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29761078/novel-immunotherapy-options-for-extranodal-nk-t-cell-lymphoma
#16
REVIEW
Boyu Hu, Yasuhiro Oki
Extranodal NK/T-cell lymphoma (ENKTCL) is a highly aggressive mature NK/T-cell neoplasm marked by NK-cell phenotypic expression of CD3ε and CD56. While the disease is reported worldwide, there is a significant geographic variation with its highest incidence in East Asian countries possibly related to the frequent early childhood exposure of Epstein-Barr virus (EBV) and specific ethnic-genetical background, which contributes to the tumorigenesis. Historically, anthracycline-based chemotherapy such as CHOP (cyclophosphamide, adriamycin, vincristine, and prednisone) was used, but resulted in poor outcomes...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29758590/interobserver-variation-in-cd30-immunohistochemistry-interpretation-consequences-for-patient-selection-for-targeted-treatment
#17
Lianne Koens, Peter M van de Ven, Nathalie J Hijmering, Marie José Kersten, Arjan Diepstra, Martine Chamuleau, Daphne de Jong
CD30 immunohistochemistry (IHC) in malignant lymphoma is used for selection of patients in clinical trials using brentuximab vedotin, an antibody drug-conjugate targeting the CD30 molecule. For reliable implementation in daily practice and meaningful selection of patients for clinical trials, information on technical variation and interobserver reproducibility of CD30 IHC staining is required. We conducted a 3-round reproducibility assessment of CD30 scoring for categorized frequency and intensity, including a technical validation, a "live polling" pre- and post-instruction scoring round, and a web-based round including individual scoring with additional IHC information to mimic daily diagnostic practice...
May 14, 2018: Histopathology
https://www.readbyqxmd.com/read/29758393/phase-i-trial-of-brentuximab-vedotin-for-steroid-refractory-chronic-graft-versus-host-disease-after-allogeneic-hematopoietic-cell-transplantation
#18
Zachariah DeFilipp, Shuli Li, Maria E Kempner, Jami Brown, Candice Del Rio, Betsy Valles, Chrisa Hunnewell, Meredith Saylor, Julie Vanderklish, Bimalangshu R Dey, Areej El-Jawahri, Steven L McAfee, Thomas R Spitzer, Yi-Bin Chen
We conducted a phase I study of brentuximab vedotin (BV), an antibody-drug conjugate targeting CD30, for the treatment of steroid-refractory chronic graft-versus-host disease (cGVHD). A modified 3 + 3 study design was used with the primary endpoint to determine the maximum tolerated dose of BV in this population. Escalating doses of BV were planned, starting with .6 mg/kg every 3 weeks (dose level 0) and increasing by .3 mg/kg per dose level. BV was administered in 21-day cycles for up to 16 cycles of therapy...
May 24, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29753846/role-of-hnf1%C3%AE-in-the-differential-diagnosis-from-other-germ-cell-tumors
#19
Anne-Laure Rougemont, Jean-Christophe Tille
Identification of the yolk sac tumor (YST) component in germ cell tumors (GCT) may prove challenging, and highly sensitive and specific immunohistochemical markers are still lacking. Preliminary data from the literature suggest that HNF1β may represent a sensitive marker of YST. The specificity of HNF1β has not been addressed in GCT. A cohort of 49 YST specimens from 45 patients was designed, occurring either as pure tumors, or as a component of a mixed GCT. Immunohistochemistry was conducted on whole tumor sections using HNF1β...
May 10, 2018: Human Pathology
https://www.readbyqxmd.com/read/29747676/epithelioid-cell-histiocytoma-with-sqstm1-alk-fusion-a-case-report
#20
Ryuko Nakayama, Yuki Togashi, Satoko Baba, Yo Kaku, Yuki Teramoto, Takaki Sakurai, Hironori Haga, Kengo Takeuchi
BACKGROUND: Epithelioid cell histiocytoma (ECH), which is also known as epithelioid benign fibrous histiocytoma, has been classified as a rare variant of fibrous histiocytoma (FH). However, the recent detection of ALK protein expression and/or ALK gene rearrangement in ECH suggests that it might be biologically different from conventional FH. CASE PRESENTATION: A 27-year-old male presented with nodule on his left foot, which had been present for 5 years. A macroscopic examination revealed an exophytic, hyperkeratotic nodule on the dorsum of the left foot...
May 10, 2018: Diagnostic Pathology
keyword
keyword
73698
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"